Whitepapers , Peptide Drug Development , Oral Peptides

How to Optimize CMC and Clinical Strategies for Injectable & Oral Peptide Drugs

18 May 2025
Overview

The exquisite specificity/selectivity, potency, and low toxicity of peptides make them attractive drug candidates. However, their rapid clearance, poor permeability, and potential instability (e.g., in solution and physiological environments) can make them challenging to develop. 

But recent advances in drug discovery and peptide engineering have led to significant progress in overcoming such challenges. 

Download
Date
18 May 2025

Learn more about Translational Pharmaceutics®:

Latest News
News & Announcements, Nottingham, UK, Artificial Intelligence, Translational Pharmaceutics®, Formulation Development Quotient Sciences and Acesion Pharma Announce Collaboration on AI-Enhanced Formulation Development to Advance Atrial Fibrillation Pipeline By: Dr. Andrew Lewis
Read More
News & Announcements, Artificial Intelligence, Translational Pharmaceutics®, Formulation Development Quotient Sciences shortlisted for "Best Use of AI in Clinical Development & Trial Innovation" at the Scrip Awards 2026 By: Dr. Andrew Lewis
Read More
News & Announcements, Nottingham, UK, Artificial Intelligence, Translational Pharmaceutics®, Formulation Development Quotient Sciences Proprietary AI-Enhanced Solution Optimizes Formulation in Clinical Study By: Dr. Andrew Lewis
Read More
Let's Talk
Where integrated CRDMO services bring therapies to life. Start a conversation today.